<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613066</url>
  </required_header>
  <id_info>
    <org_study_id>Emato68</org_study_id>
    <nct_id>NCT01613066</nct_id>
  </id_info>
  <brief_title>Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies</brief_title>
  <official_title>Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Santa Croce-Carle Cuneo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Santa Croce-Carle Cuneo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cord blood (CB) from an unrelated donor is increasingly used an alternative source of
      hematopoietic stem cells for adults with hematologic malignancies who lack an HLA-matched
      donor. However, the utilization of single-unit CB for transplantation of adult patients has
      been impeded by the low number of nucleated cells available from individual CB units. Direct
      intrabone CB injection (IBCBi) has been recently investigated as a solution to cell dose
      problem in adults, with the aims of minimizing non-specific loss of progenitors. We set up a
      phase I-II study to assess the safety and efficacy of CB transplantation by IBCBi in adult
      patients with advanced or high-risk hematological malignancies
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to neutrophil recovery</measure>
    <time_frame>28 days after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of platelet engraftment</measure>
    <time_frame>100 days after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft versus host disease</measure>
    <time_frame>100 days after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft Versus Host Disease</measure>
    <time_frame>One year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>One year after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>High Risk Haematological Malignancies</condition>
  <condition>Advanced Haematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with high risk haematological malignancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrabone Allogeneic Transplant</intervention_name>
    <description>Unrelated single unit intrabone cord blood transplantation</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or High Risk Haematological Malignancies

          -  Age 18-65 years

          -  no suitable unrelated HLA-matched donors identified in a clinically useful time-frame

          -  Informed consent

        Exclusion Criteria:

          -  Active infectious disease at inclusion

          -  HIV- positivity or active hepatitis infection

          -  Impaired liver function (Bilirubin &gt; upper normal limit; Transaminases &gt; 3.0 x upper
             normal limit) at inclusion

          -  Impaired renal function (Creatinine-clearance &lt;60 ml/min; Serum Creatinine &gt;1.5 x
             upper normal limit) at inclusion

          -  Psychiatric diseases or conditions that might impair the ability to give informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniele Mattei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASO S Croce e Carle</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto Sorasio, Head, MD</last_name>
    <phone>+390171642229</phone>
    <email>rsorasio@inwind.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniele Mattei, MD</last_name>
    <phone>+390171642229</phone>
    <email>mattei.d@ospedale.cuneo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera S Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Mattei, MD</last_name>
      <phone>+390171642229</phone>
      <email>mattei.d@ospedale.cuneo.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberto Sorasio, MD</last_name>
      <phone>+390171642229</phone>
      <email>rsorasio@inwind.it</email>
    </contact_backup>
    <investigator>
      <last_name>Daniele Mattei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Frassoni F, Gualandi F, Podest√† M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008 Sep;9(9):831-9. doi: 10.1016/S1470-2045(08)70180-3. Epub 2008 Aug 8.</citation>
    <PMID>18693069</PMID>
  </reference>
  <reference>
    <citation>Page KM, Zhang L, Mendizabal A, Wease S, Carter S, Gentry T, Balber AE, Kurtzberg J. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant. 2011 Sep;17(9):1362-74. doi: 10.1016/j.bbmt.2011.01.011. Epub 2011 Jan 28.</citation>
    <PMID>21277377</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2012</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Santa Croce-Carle Cuneo</investigator_affiliation>
    <investigator_full_name>Roberto Sorasio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Haematological malignancies</keyword>
  <keyword>Allogeneic Cord Blood transplantation</keyword>
  <keyword>Intrabone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

